Intellectual Property is the lifeblood of the biopharmaceutical industry. The shifting legal landscape and budgetary pressures make it ever more challenging to effectively protect and exploit IP assets.

Our panel of experts will discuss their views on these and other topics:

• Impact of the patent reform on patent filing strategies
• Subject matter eligibility under Myriad and Prometheus: US v. Rest of the World
• How to properly project IP expenses and maximize ROI short and long-term
• Balancing disclosure, ownership, enablement and obviousness in charting out an IP strategy
• Major legal differences between biological and chemical entities
• Tools and resources available to for patent analyses and IP management

Speakers:

• Steven A. Kriston, JD,  Regional Consultant, Innovation and Asset Management, IP Solutions, Thomson Reuters
• Robert Silverman, JD, PhD, Sr. Vice President and General Counsel, Concert Pharmaceuticals
• Jennifer Zarutskie Sieczkiewicz, JD, PhD, Director of IP Strategy and Operations, Biogen Idec

Moderator:

• Konstantin Linnik, JD, PhD, Partner, Intellectual Property Department, Nutter McClennen & Fish LLP